Asian Journal of Medicine and Health

This study presents a scientific exploration into the epidemiology, causative agents, diagnostic advancements, and control strategies of hospital-acquired infections (HAIs), aiming to provide an evidence-based foundation for improved clinical and public health interventions. Hospital-acquired infections, also known as nosocomial infections, are infections that patients acquire during their stay in a healthcare setting which were neither present nor incubating at the time of admission. These infections remain a major global health concern, contributing significantly to patient morbidity, prolonged hospital stays, increased medical costs, and mortality. HAIs manifest in several forms, with the most common types being catheter-associated urinary tract infections (CAUTIs), surgical site infections (SSIs), ventilator-associated pneumonia (VAP), and central line-associated bloodstream infections (CLABSIs). A wide range of opportunistic and multidrug-resistant pathogens are responsible, including Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and many of which have developed resistance to last-resort antibiotics such as carbapenems. According to the World Health Organization, in low- and middle-income countries, 1 in 10 hospitalized patients will acquire at least one HAI. Globally, HAIs contribute to nearly 1.4 million deaths annually, with antimicrobial-resistant pathogens responsible for an estimated 700,000 deaths—a number projected to rise to 10 million by 2050 if no action is taken. Case studies have demonstrated the potential of these tools in reducing HAI incidence when implemented as part of a broader infection control framework. In this review, we discuss early and advanced diagnostic techniques for bacteriological examinations such as, PCR-based pathogen identification, antibiotic susceptibility profiling surveillance technologies, MALDI-TOF MS, and machine learning-based monitoring systems. Furthermore, we highlighted the promise of novel therapeutics—such as bacteriophage therapy and microbiome-based interventions.